- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
The worldwide market for Targeted Cancer Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Targeted Cancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Cancer Growth Blocker Drug
Monoclonal Antibody
Other
Market Segment by Applications, can be divided into
Hospitals
Academic & Research Institutes
Diagnostic & Reference Laboratories
There are 15 Chapters to deeply display the global Targeted Cancer Drugs market.
Chapter 1, to describe Targeted Cancer Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Targeted Cancer Drugs, with sales, revenue, and price of Targeted Cancer Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Targeted Cancer Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and , to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Targeted Cancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Targeted Cancer Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Targeted Cancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Cancer Growth Blocker Drug
1.2.2 Monoclonal Antibody
1.2.3 Other
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Academic & Research Institutes
1.3.3 Diagnostic & Reference Laboratories
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Targeted Cancer Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Incyte
2.2.1 Business Overview
2.2.2 Targeted Cancer Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Incyte Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Targeted Cancer Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Eli Lilly
2.4.1 Business Overview
2.4.2 Targeted Cancer Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Eli Lilly Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Gilead
2.5.1 Business Overview
2.5.2 Targeted Cancer Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Gilead Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Sanofi
2.6.1 Business Overview
2.6.2 Targeted Cancer Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Sanofi Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Galapagos
2.7.1 Business Overview
2.7.2 Targeted Cancer Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Galapagos Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 AbbVie
2.8.1 Business Overview
2.8.2 Targeted Cancer Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AbbVie Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Vertex
2.9.1 Business Overview
2.9.2 Targeted Cancer Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Vertex Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Teva
2.10.1 Business Overview
2.10.2 Targeted Cancer Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Astellas Pharma
2.11.1 Business Overview
2.11.2 Targeted Cancer Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Astellas Pharma Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Celgene
2.12.1 Business Overview
2.12.2 Targeted Cancer Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Celgene Targeted Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Targeted Cancer Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Targeted Cancer Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Targeted Cancer Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Targeted Cancer Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Targeted Cancer Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Targeted Cancer Drugs Market Analysis by Regions
4.1 Global Targeted Cancer Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Targeted Cancer Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Targeted Cancer Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
4.5 South America Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
5 North America Targeted Cancer Drugs by Countries
5.1 North America Targeted Cancer Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Targeted Cancer Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Targeted Cancer Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
6 Europe Targeted Cancer Drugs by Countries
6.1 Europe Targeted Cancer Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Targeted Cancer Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Targeted Cancer Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
6.3 UK Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
6.4 France Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Targeted Cancer Drugs by Countries
7.1 Asia-Pacific Targeted Cancer Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Targeted Cancer Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Targeted Cancer Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
7.5 India Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
8 South America Targeted Cancer Drugs by Countries
8.1 South America Targeted Cancer Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Targeted Cancer Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Targeted Cancer Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Targeted Cancer Drugs by Countries
9.1 Middle East and Africa Targeted Cancer Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Targeted Cancer Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Targeted Cancer Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Targeted Cancer Drugs Sales and Growth Rate (2013-2018)
10 Global Targeted Cancer Drugs Market Segment by Type
10.1 Global Targeted Cancer Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Targeted Cancer Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Targeted Cancer Drugs Revenue and Market Share by Type (2013-2018)
10.2 Cancer Growth Blocker Drug Sales Growth and Price
10.2.1 Global Cancer Growth Blocker Drug Sales Growth (2013-2018)
10.2.2 Global Cancer Growth Blocker Drug Price (2013-2018)
10.3 Monoclonal Antibody Sales Growth and Price
10.3.1 Global Monoclonal Antibody Sales Growth (2013-2018)
10.3.2 Global Monoclonal Antibody Price (2013-2018)
10.4 Other Sales Growth and Price
10.4.1 Global Other Sales Growth (2013-2018)
10.4.2 Global Other Price (2013-2018)
11 Global Targeted Cancer Drugs Market Segment by Application
11.1 Global Targeted Cancer Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Academic & Research Institutes Sales Growth (2013-2018)
11.4 Diagnostic & Reference Laboratories Sales Growth (2013-2018)
12 Targeted Cancer Drugs Market Forecast (2018-2023)
12.1 Global Targeted Cancer Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Targeted Cancer Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Targeted Cancer Drugs Market Forecast (2018-2023)
12.2.2 Europe Targeted Cancer Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Targeted Cancer Drugs Market Forecast (2018-2023)
12.2.4 South America Targeted Cancer Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Targeted Cancer Drugs Market Forecast (2018-2023)
12.3 Targeted Cancer Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Targeted Cancer Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Targeted Cancer Drugs Market Share Forecast by Type (2018-2023)
12.4 Targeted Cancer Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Targeted Cancer Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Targeted Cancer Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Targeted Cancer Drugs Picture
Table Product Specifications of Targeted Cancer Drugs
Figure Global Sales Market Share of Targeted Cancer Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
